How GLP-1 Peptides Work in the Brain: Appetite, Reward, and Satiety

While GLP-1 is primarily known as a gut hormone released after eating, its receptors are expressed throughout the central nervous system. Key brain regions with GLP-1 receptor expression include:

• Hypothalamus — particularly the arcuate nucleus (ARC) and paraventricular nucleus (PVN), which integrate energy balance signals
• Brainstem — the nucleus tractus solitarius (NTS) and area postrema, which receive vagal signals from the gut and regulate meal termination
• Ventral tegmental area (VTA) and nucleus accumbens — components of the mesolimbic dopamine reward circuit
• Hippocampus — involved in memory consolidation of food-related cues

This widespread expression means GLP-1 receptor agonism simultaneously engages multiple neural circuits involved in hunger, satiety, and food reward — a more comprehensive effect on appetite regulation than was initially appreciated.

The arcuate nucleus of the hypothalamus contains two opposing neuronal populations that regulate energy balance:

• AgRP/NPY neurons — promote hunger and reduce energy expenditure when activated
• POMC/CART neurons — suppress appetite and increase energy expenditure when activated

GLP-1 receptor activation in the ARC suppresses AgRP/NPY neuron activity and stimulates POMC/CART neurons, shifting the hypothalamic balance toward satiety. Research in rodent models has confirmed that hypothalamic GLP-1 receptor blockade attenuates the appetite-suppressing effects of peripherally administered GLP-1 agonists, confirming central mechanisms are necessary — not just peripheral gut effects.

The nucleus tractus solitarius (NTS) in the brainstem is a primary integration point for peripheral satiety signals. It receives direct vagal innervation from the gut and is densely populated with GLP-1 receptors. When GLP-1 agonists engage NTS receptors, they amplify meal-termination signals that travel both upward to the hypothalamus and downward to regulate gastric motility.

The area postrema — the brain's "chemoreceptor trigger zone" — is also GLP-1 receptor-positive. This is relevant to the nausea side effects observed at higher doses of GLP-1 agonists: the area postrema is responsible for initiating nausea responses, and its activation by GLP-1 agonists at supratherapeutic concentrations is the likely mechanism of dose-limiting nausea in clinical settings.

Perhaps the most surprising finding in recent GLP-1 research has been evidence for effects on the mesolimbic dopamine reward circuit. GLP-1 receptors are expressed on dopaminergic neurons in the ventral tegmental area and on neurons in the nucleus accumbens — the brain's primary reward centre.

Studies have shown that GLP-1 receptor agonism:

• Reduces dopamine release in the nucleus accumbens in response to palatable food
• Decreases preference for high-fat and high-sugar foods beyond what would be expected from caloric restriction alone
• Attenuates cue-induced food craving in both preclinical and clinical research settings

This dopaminergic mechanism may explain why subjects on GLP-1 agonists often report reduced cravings for specific "rewarding" foods — not simply feeling less hungry, but caring less about food altogether. Emerging research is exploring implications for addiction neuroscience beyond food, including alcohol and substance use disorders.

The addition of GIP receptor co-agonism in Tirzepatide and Retatrutide adds another layer of central nervous system activity. GIP receptors are expressed in the hippocampus, cortex, and hypothalamus. Research suggests GIP receptor activation in the brain:

• Synergises with GLP-1R signalling in hypothalamic appetite circuits
• May reduce the nausea associated with GLP-1 monotherapy by modulating area postrema sensitivity
• Potentially contributes to the enhanced weight outcomes of dual and triple agonists beyond the additive effect of peripheral receptor activation

The central mechanisms of GIP receptor agonism are less well characterised than those of GLP-1, making this an active and open area of research interest.